Vigil Neuroscience
VIGL
VIGL was delisted on the 4th of August, 2025.
35 hedge funds and large institutions have $44.7M invested in Vigil Neuroscience in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.83% less ownership
Funds ownership: 63.18% → 61.35% (-1.8%)
26% less funds holding
Funds holding: 47 → 35 (-12)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
64% less capital invested
Capital invested by funds: $125M → $44.7M (-$80.4M)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$514K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$88K |
| 3 |
Renaissance Technologies
New York
|
+$68.9K |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$56.6K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$788K |
| 2 |
Squarepoint
New York
|
-$606K |
| 3 |
CCM
CAAS Capital Management
New York
|
-$527K |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$319K |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
-$211K |
VIGL Hedge Fund Activity: Q2 2022 in Review
35 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q2 2022, worth a combined $44.7M — down 64% from $125M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VIGL and 6 opened new positions — a net loss of 11 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $514K. The largest seller was BlackRock, cutting an estimated $788K.
- 35 institutional investors held Vigil Neuroscience (VIGL) as of Q2 2022, down from 47 in Q1 2022.
- Funds reported $44.7M of Vigil Neuroscience stock for Q2 2022, down 64% quarter-over-quarter.
- 6 funds opened new Vigil Neuroscience positions in Q2 2022 and 17 closed out, a net change of -11 holders.
- The largest Vigil Neuroscience buyer in Q2 2022 was Laurion Capital Management, an estimated $514K added.
- The largest Vigil Neuroscience seller in Q2 2022 was BlackRock, an estimated $788K sold.
Based on aggregated 13F filings for Q2 2022.